{
    "xml": "<topic id=\"PHP106893\" outputclass=\"drug\" rev=\"1.13\" type=\"drug\" namespace=\"/drugs/simeprevir\" basename=\"simeprevir\" title=\"SIMEPREVIR\">\n<title>SIMEPREVIR</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1298\" namespace=\"/interactions/list-of-drug-interactions/antivirals/simeprevir\">Simeprevir</xref>\n</p>\n<data name=\"vtmid\">24601811000001103</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_321881277\" title=\"Protease inhibitors (hepatitis)\">Protease inhibitors (hepatitis)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP106932\" outputclass=\"indicationsAndDose\" rev=\"1.11\" parent=\"/drugs/simeprevir\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">In combination with ribavirin and peginterferon alfa for chronic hepatitis C infection of genotype 1 or 4</p>\n<p outputclass=\"therapeuticIndication\">In combination with sofosbuvir (with or without ribavirin) for urgent treatment of chronic hepatitis C infection of genotype 1 or 4 when peginterferon alfa cannot be used because of intolerance or contra-indications</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;mg once daily (for duration of treatment consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP106925\" outputclass=\"cautions\" rev=\"1.12\" parent=\"/drugs/simeprevir\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Consider alternative treatment in presence of NS3 Q80K polymorphism&#8212;efficacy of simeprevir is reduced</ph>; <ph outputclass=\"caution\">patients of East Asian origin</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP106933\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/simeprevir\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (simeprevir).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP106938\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/simeprevir\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Constipation</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">fatigue (in combination with sofosbuvir)</ph>; <ph outputclass=\"sideEffect\">headache (in combination with sofosbuvir)</ph>; <ph outputclass=\"sideEffect\">insomnia (in combination with sofosbuvir)</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">photosensitivity</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">raised bilirubin concentration</ph>; <ph outputclass=\"sideEffect\">rash</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Rash</p>\n<p>Monitor for deterioration if mild or moderate; discontinue if severe.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP106926\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/simeprevir\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Effective contraception essential during treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP106934\" outputclass=\"pregnancy\" parent=\"/drugs/simeprevir\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;toxicity in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP106924\" outputclass=\"breastFeeding\" parent=\"/drugs/simeprevir\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in plasma of breast-fed <i>animals</i>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP106931\" outputclass=\"hepaticImpairment\" parent=\"/drugs/simeprevir\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution in moderate to severe impairment&#8212;elimination reduced in severe impairment.</p>\n<p>Manufacturer advises caution in decompensated cirrhosis&#8212;elimination reduced in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP106936\" outputclass=\"renalImpairment\" parent=\"/drugs/simeprevir\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;elimination may be reduced.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP106937\" outputclass=\"preTreatmentScreening\" rev=\"1.13\" parent=\"/drugs/simeprevir\">\n<title>Pre-treatment screening</title>\n<body>\n<section>\n<sectiondiv>\n<p>Test for NS3 Q80K polymorphism before combination treatment with ribavirin and peginterferon alfa in patients with chronic hepatitis C infection of genotype 1a.</p>\n<p>Consider testing for NS3 Q80K polymorphism before combination treatment with sofosbuvir (with or without ribavirin) in patients with chronic hepatitis C infection of genotype 1a.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP106935\" outputclass=\"patientAndCarerAdvice\" rev=\"1.8\" parent=\"/drugs/simeprevir\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"adviceAroundMissedDoses\">\n<title>Missed doses</title>\n<sectiondiv>\n<p>If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time. </p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP106945\" outputclass=\"nationalFunding\" rev=\"1.9\" parent=\"/drugs/simeprevir\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA331</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (February 2015)</p>\r\n<p>Simeprevir in combination with peginterferon alfa and ribavirin, is recommended within its marketing authorisation, as an option for the treatment of chronic hepatitis C infection of genotype 1 and 4 in adults.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA331\">www.nice.org.uk/TA331</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP106893-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/simeprevir\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP106977\" title=\"Capsule\" namespace=\"/drugs/simeprevir/capsule\">Capsule</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107699\" namespace=\"/about/changes\" title=\"Changes\" count=\"1\" rel=\"backlink\">Changes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78120\" namespace=\"/treatment-summaries/respiratory-syncytial-virus\" title=\"Respiratory syncytial virus\" count=\"1\" rel=\"backlink\">Respiratory syncytial virus</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78240\" namespace=\"/treatment-summaries/hepatitis\" title=\"Hepatitis\" count=\"3\" rel=\"backlink\">Hepatitis</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1298\" namespace=\"/interactions/list-of-drug-interactions/antivirals/simeprevir\" title=\"Simeprevir\" count=\"1\" rel=\"link\">Simeprevir</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP106977\" namespace=\"/drugs/simeprevir/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n</links>\n</topic>",
    "id": "PHP106893",
    "outputclass": "drug",
    "rev": "1.13",
    "type": "drug",
    "namespace": "/drugs/simeprevir",
    "basename": "simeprevir",
    "title": "SIMEPREVIR",
    "interactants": [
        {
            "id": "bnf_int_1298",
            "label": "Simeprevir"
        }
    ],
    "vtmid": "24601811000001103",
    "drugClassification": [
        "Protease inhibitors (hepatitis)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "In combination with ribavirin and peginterferon alfa for chronic hepatitis C infection of genotype 1 or 4",
                        "html": "In combination with ribavirin and peginterferon alfa for chronic hepatitis C infection of genotype 1 or 4"
                    },
                    {
                        "textContent": "In combination with sofosbuvir (with or without ribavirin) for urgent treatment of chronic hepatitis C infection of genotype 1 or 4 when peginterferon alfa cannot be used because of intolerance or contra-indications",
                        "html": "In combination with sofosbuvir (with or without ribavirin) for urgent treatment of chronic hepatitis C infection of genotype 1 or 4 when peginterferon alfa cannot be used because of intolerance or contra-indications"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "150 mg once daily (for duration of treatment consult product literature).",
                        "html": "<p>150&#8239;mg once daily (for duration of treatment consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Consider alternative treatment in presence of NS3 Q80K polymorphism&#8212;efficacy of simeprevir is reduced",
                "html": "Consider alternative treatment in presence of NS3 Q80K polymorphism&#8212;efficacy of simeprevir is reduced"
            },
            {
                "type": "cautions",
                "textContent": "patients of East Asian origin",
                "html": "patients of East Asian origin"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (simeprevir).",
                "html": "<p>Appendix 1 (simeprevir).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Constipation",
                        "html": "Constipation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fatigue (in combination with sofosbuvir)",
                        "html": "fatigue (in combination with sofosbuvir)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "headache (in combination with sofosbuvir)",
                        "html": "headache (in combination with sofosbuvir)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "insomnia (in combination with sofosbuvir)",
                        "html": "insomnia (in combination with sofosbuvir)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "photosensitivity",
                        "html": "photosensitivity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "raised bilirubin concentration",
                        "html": "raised bilirubin concentration",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Rash",
                "textContent": "Monitor for deterioration if mild or moderate; discontinue if severe.",
                "html": "<p>Monitor for deterioration if mild or moderate; discontinue if severe.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Effective contraception essential during treatment.",
                "html": "<p>Effective contraception essential during treatment.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use only if potential benefit outweighs risk&#8212;toxicity in animal studies.",
                "html": "<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;toxicity in <i>animal</i> studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in plasma of breast-fed animals.",
                "html": "<p>Manufacturer advises avoid&#8212;present in plasma of breast-fed <i>animals</i>.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution in moderate to severe impairment&#8212;elimination reduced in severe impairment.\n\nManufacturer advises caution in decompensated cirrhosis&#8212;elimination reduced in severe impairment.",
                "html": "<p>Manufacturer advises caution in moderate to severe impairment&#8212;elimination reduced in severe impairment.</p><p>Manufacturer advises caution in decompensated cirrhosis&#8212;elimination reduced in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution if eGFR less than 30 mL/minute/1.73 m2&#8212;elimination may be reduced.",
                "html": "<p>Manufacturer advises caution if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;elimination may be reduced.</p>"
            }
        ]
    },
    "preTreatmentScreening": {
        "preTreatmentScreening": [
            {
                "type": "preTreatmentScreening",
                "textContent": "Test for NS3 Q80K polymorphism before combination treatment with ribavirin and peginterferon alfa in patients with chronic hepatitis C infection of genotype 1a.\n\nConsider testing for NS3 Q80K polymorphism before combination treatment with sofosbuvir (with or without ribavirin) in patients with chronic hepatitis C infection of genotype 1a.",
                "html": "<p>Test for NS3 Q80K polymorphism before combination treatment with ribavirin and peginterferon alfa in patients with chronic hepatitis C infection of genotype 1a.</p><p>Consider testing for NS3 Q80K polymorphism before combination treatment with sofosbuvir (with or without ribavirin) in patients with chronic hepatitis C infection of genotype 1a.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundMissedDoses": [
            {
                "type": "adviceAroundMissedDoses",
                "textContent": "If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.",
                "html": "<p>If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time. </p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA331",
                        "label": "www.nice.org.uk/TA331"
                    }
                ],
                "fundingIdentifier": "NICE TA331",
                "textContent": "Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (February 2015) Simeprevir in combination with peginterferon alfa and ribavirin, is recommended within its marketing authorisation, as an option for the treatment of chronic hepatitis C infection of genotype 1 and 4 in adults.\n\nwww.nice.org.uk/TA331",
                "html": "<p outputclass=\"title\">Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (February 2015)</p> <p>Simeprevir in combination with peginterferon alfa and ribavirin, is recommended within its marketing authorisation, as an option for the treatment of chronic hepatitis C infection of genotype 1 and 4 in adults.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA331\">www.nice.org.uk/TA331</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP106977",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP107699",
                "label": "Changes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78120",
                "label": "Respiratory syncytial virus",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78240",
                "label": "Hepatitis",
                "type": "treatmentSummary"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1298",
                "label": "Simeprevir",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP106977",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    }
}